ERBB2 and heart failure: Among HER2 + patients, trastuzumab use showed similar patterns, with prevalence of 630/1,100 [57.3%] vs 2,279/2,866 [79.5%] for any vs no prior CVD (crude PR = 0.72, 0.68–0.76, adjusted PR = 0.95, 0.90–0.99); adjusted PRs for specific outcomes ranged from 0.77 (0.61–0.93) for heart failure, to 1.04 (0.92–1.15) for VTE.